Stocktoria
Seres Therapeutics, Inc. MCRB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-06-26
Chart by TradingView
5/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $789,000 | $0 | $0 | $7.1M | $144.9M |
| Operating income | -$94.0M | -$121.3M | -$195.1M | -$179.9M | -$64.5M |
| Net income | $5.7M | $136,000 | -$113.7M | -$250.2M | -$65.6M |
| Operating cash flow | $1.1M | -$148.6M | -$117.4M | -$228.8M | $6.7M |
| Free cash flow | $865,000 | -$149.0M | -$125.3M | -$238.6M | -$2.9M |
| Total assets | $138.2M | $139.8M | $358.6M | $348.8M | $354.9M |
| Total liabilities | $94.0M | $126.0M | $403.5M | $338.0M | $223.4M |
| Shareholders' equity | $44.2M | $13.8M | -$44.9M | $10.8M | $131.5M |
| Ratios | |||||
| Operating margin | -11910.1% | — | — | -2524.0% | -44.5% |
| Net margin | 721.9% | — | — | -3509.5% | -45.2% |
| FCF margin | 109.6% | — | — | -3347.9% | -2.0% |
| Return on assets | 4.1% | 0.1% | -31.7% | -71.7% | -18.5% |
| Return on equity | 12.9% | 1.0% | 253.5% | -2319.9% | -49.9% |
| Debt / equity | — | — | -2.45× | 4.64× | 0.18× |
| Current ratio | 2.56 | 0.94 | 1.78 | 2.28 | 3.69 |
| Revenue growth | — | — | -100.0% | -95.1% | 1118.2% |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001609809 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.